Related Experiment Video
Updated: May 11, 2025

Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
Published on: August 3, 2021
UDP-glucose dehydrogenase variants cause dystroglycanopathy
Anna M Reelfs1, Carrie M Stephan2, Theresa M Czech2,3
1University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Insights
Genetic variants in UDP-glucose dehydrogenase (UGDH) cause a rare neuromuscular disorder. This study identifies UGDH as a new gene linked to dystroglycanopathy, a condition affecting muscle and brain development.
Area of Science:
- Genetics
- Neuromuscular Disorders
- Biochemistry
Background:
- UDP-glucose dehydrogenase (UGDH) gene variants are implicated in developmental disorders like hypotonia, developmental delay, and epilepsy.
- Dystroglycanopathies are a group of inherited neuromuscular disorders characterized by impaired muscle development and often brain abnormalities.
Observation:
- This study presents the first pathologic evidence of dystroglycanopathy in siblings with identified UGDH variants.
- Both siblings exhibited developmental delay and elevated creatinine kinase levels starting around six months of age.
- Sibling A later developed epilepsy and underwent a muscle biopsy revealing necrotizing myopathy and reduced matriglycan, with Western blot showing low molecular weight alpha-dystroglycan.
Findings:
- The siblings carried pathogenic UDP-glucose dehydrogenase (UGDH) variants in trans: c.305G>A p.(R102Q), predicted to disrupt protein structure, and c.265-6C>G, which affects splicing.
- Pathologic findings in muscle tissue, including reduced matriglycan and altered alpha-dystroglycan, confirm a dystroglycanopathy phenotype.
- The identified UGDH variants are strongly associated with the observed clinical symptoms and pathological muscle changes.
Implications:
- UDP-glucose dehydrogenase (UGDH) is proposed as an additional gene associated with dystroglycanopathies.
- This finding expands the genetic landscape of neuromuscular disorders and provides new insights into the molecular mechanisms of dystroglycanopathies.
- Understanding the role of UGDH in dystroglycanopathy may lead to improved diagnostic approaches and potential therapeutic strategies for affected individuals.
Abstract:
UDP-glucose dehydrogenase (UGDH) variants have been associated with hypotonia, developmental delay, and epilepsy. We report the first pathologic evidence of dystroglycanopathy in siblings with UGDH variants. Both presented around 6 months with developmental delay and elevated creatinine kinase. Sibling A developed epilepsy at age 9 years. Muscle biopsy from sibling A showed necrotizing myopathy with reduced matriglycan immunostaining. Western blot revealed α-dystroglycan with abnormally low molecular weight. The siblings shared pathogenic UGDH variants in trans: c.305G>A p.(R102Q) is predicted to disrupt protein structure and function; c.265-6C>G is deleterious to splicing. We propose that UGDH is an additional dystroglycanopathy gene.
More Related Videos
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Proteoglycans
Inborn Errors of Metabolism
Lysosomal Hydrolases
Satellite Stem Cells and Muscular Dystrophy
Oligosaccharide Assembly
Multiple sugar molecules that may or may...

